Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ: ELTX )

8.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per... 
Via Benzinga
Over $2M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
A Look At Elicio Therapeutics’ (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?
--News Direct-- 
Via News Direct
A Look At Elicio Therapeutics' (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?
Elicio Therapeutics Inc. (NYSE: ELTX) is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. 
Via Benzinga
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System
--News Direct-- 
Via News Direct
Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System
An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have... 
Via Benzinga
How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030
--News Direct-- 
Via News Direct
How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030
Founded in 2011, Elicio Therapeutics Inc. (NASDAQ: ELTX) strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and... 
Via Benzinga
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
From Elicio Therapeutics Inc.
Via GlobeNewswire
US Stocks Mixed; SAIC Posts Upbeat Results
U.S. stocks traded mixed this morning, with Dow Jones dropping around 20 points on Monday. Following the market opening Monday, the Dow traded down 0.06% to 33,740.98 while the NASDAQ rose 0.08% to... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.